DEA Prescription Drug Monitoring Program Audit Defense Lawyer: 21 U.S.C. § 822

A DEA audit does not arrive with a warning. Diversion investigators appear at a pharmacy or practice, request access to prescription logs and inventory records, and begin asking questions before any attorney has been called.

The registrant's instinct is often to cooperate, to explain, and to treat the visit as a compliance matter rather than a criminal one. That instinct can be a serious mistake.

21 U.S.C. § 822 is the registration provision at the heart of the Controlled Substances Act, the statute that authorizes every physician, pharmacist, and dispenser to handle controlled substances at all.

When the DEA finds registration violations, recordkeeping failures, or prescribing patterns it considers suspicious, the consequence is not always a civil fine.

It can be the start of a criminal case under 21 U.S.C. § 841, the federal drug distribution statute, which carries penalties comparable to those imposed on street-level traffickers.

What 21 U.S.C. § 822 Requires

Section 822 requires every person who manufactures or distributes any controlled substance to obtain annual registration from the Attorney General, and every person who dispenses any controlled substance to obtain registration as well.

Registration is issued separately for each physical practice location and each regulated activity category. A physician practicing at two clinic addresses must therefore maintain two independent registrations, and a single lapse in renewal creates immediate legal exposure.

The DEA may deny registration to any applicant whose record is inconsistent with the public interest standard under 21 U.S.C. § 823, a broad standard that encompasses prior convictions, disciplinary history, and patterns of irregular prescribing.

When the DEA revokes or suspends a registration, the registrant is immediately prohibited from handling any controlled substance, which can shut down a medical practice or pharmacy operation without advance notice.

Registration suspension or revocation is the administrative track. The criminal track runs parallel to it, and the two do not wait for each other.

How a DEA Audit Becomes a Criminal Investigation

For medical providers and pharmacists, the DEA pharmacy audit primarily looks for anomalies or unusual activity in the prescribing and dispensing of controlled substances.

Even certain legal activities can trigger red flags if the DEA becomes suspicious, leading to increased scrutiny, additional audits, undercover visits, and possibly raids of a practice. The specific patterns that draw DEA's attention are well documented. These include:

filling too many opioid prescriptions from the same doctor,
an unusually high number of cash payments for opioid prescriptions,
inventory anomalies such as billing for more opioids than were dispensed,
failure to follow proper security protocols for storing or disposing of controlled substances, and
patients who travel long distances to access a particular provider.

Behind those patterns, the DEA uses Prescription Drug Monitoring Program data as its primary analytical tool.

Prescription Drug Monitoring Programs operate in 49 states, the District of Columbia, and Guam. Every controlled-substance prescription is reported:

drug name,
dose,
quantity,
dispense date,
patient information, and
prescriber information.

DEA analysts use PDMP data to identify prescribers who stand out statistically. When statistical flags appear, investigators often know the broad outlines of a case before they walk through the door.

An audit that begins as a routine inspection can shift rapidly into an evidence-gathering exercise.

The registrant who treats it as routine and answers questions without counsel present is providing testimony without any of the protections the Fifth Amendment is designed to afford.

The Criminal Exposure: From Registration to Drug Distribution Charges

Violations of the registration provisions are generally not criminal offenses in themselves, but certain serious violations may result in criminal prosecutions that yield fines and short prison sentences.

The more dangerous pathway runs through the underlying conduct that the DEA believes the registration violations conceal.

Under 21 U.S.C. § 841(a), distributing controlled substances outside the usual course of professional practice carries up to $1 million in fines for a first corporate offense and life sentences if death results.

Civil penalties for recordkeeping violations, updated in February 2024, are:

set at $18,759 per recordkeeping violation and
$80,850 per prescription violation, with
a maximum of $1,951,000 for a pattern of flagrant violations.

Those civil figures represent only the starting point.

Add criminal liability, DEA registration revocation, state license loss, and False Claims Act treble damages where Medicare or Medicaid was billed, and the total exposure can reach eight figures from a single enforcement action.

Pharmacists face identical exposure under a doctrine called corresponding responsibility.

A corresponding responsibility rests with the pharmacist who fills the prescription to ensure that it was issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice.

The person knowingly filling an invalid prescription, as well as the person issuing it, shall be subject to the penalties provided for violations of the provisions of law relating to controlled substances.

What the Ruan Decision Changed for Criminal Defense

The legal landscape for CSA criminal prosecutions shifted materially in 2022. In Ruan v. United States, the Supreme Court clarified the mental state the DEA must establish to convict a healthcare professional of illegal drug distribution.

Ruan ruled that the DEA must prove beyond a reasonable doubt that a physician knew or intended that a prescription was unlawful to subject the physician to criminal penalties under the CSA.

Before Ruan, prosecutors could convict based on an objective standard. They only needed to show that a reasonable pharmacist or physician should have known the prescriptions were illegitimate.

After Ruan, prosecutors must prove the defendant actually knew. Good faith belief is now a valid defense.

That is a significant shift, but it comes with a critical limitation. Criminal prosecution after Ruan requires proof that the defendant knew that prescribing was illegal.

Good faith defeats criminal liability. But administrative revocation operates under different standards.

The DEA can revoke registration if prescribing was inconsistent with the public interest, a standard that does not require criminal intent. This dual exposure requires a coordinated defense strategy.

A defense that protects a registrant in criminal court may create complications in simultaneous administrative proceedings.

Managing both tracks simultaneously, with counsel who understands both bodies of law, is not optional in serious DEA investigations.

Related Federal Laws

21 U.S.C. § 823 – DEA Registration Requirements and Public Interest Standard

Section 823 outlines the DEA's authority to grant, deny, renew, suspend, or revoke registrations. The DEA assesses whether a registrant's ongoing authorization aligns with the public interest by considering their compliance record, prescribing habits, and professional behavior.

21 U.S.C. § 841(a)(1) – Unlawful Distribution of Controlled Substances

This law makes it a federal offense to knowingly distribute or dispense controlled substances outside the normal scope of professional practice and without a legitimate medical purpose. Many DEA audits ultimately focus on whether there is evidence to support charges under this rule.

21 U.S.C. § 842 – Recordkeeping and Regulatory Violations

Section 842 prohibits various violations involving controlled substance records, reports, security requirements, and registration obligations. DEA audits frequently examine compliance with these recordkeeping requirements, and violations can result in substantial civil penalties.

21 U.S.C. § 843 – Fraud, Deception, and False Records

Section 843 criminalizes obtaining controlled substances through fraud, false statements, fraudulent prescriptions, and record falsification under federal drug laws. Investigators regularly review prescribing records, inventory logs, and dispensing documents to identify possible violations.

21 U.S.C. § 824 – Suspension and Revocation of DEA Registration

Section 824 grants the DEA authority to suspend or revoke a practitioner's registration if the practitioner violates federal controlled-substance laws or fails to meet registration requirements. Such actions can instantly stop physicians, pharmacists, or healthcare providers from managing controlled substances.

Why These Related Laws Matter

DEA audits seldom concentrate on just one statute. What starts as a review under 21 U.S.C. § 822 can quickly escalate to allegations related to prescribing practices, recordkeeping violations, registration problems, or controlled substance distribution.

Since administrative proceedings and criminal investigations often occur simultaneously, healthcare providers must develop a coordinated defense plan to safeguard their DEA registration, professional license, reputation, and livelihood.

Frequently Asked Questions (FAQs)

Can a DEA audit lead to criminal charges?

Yes. Although many DEA audits start as administrative compliance reviews, investigators might refer a case for criminal prosecution if they find evidence of illegal prescribing, diversion, record falsification, or violations of federal controlled substance laws. What begins as an audit can swiftly escalate into a criminal investigation.

What should I do if DEA investigators arrive at my practice or pharmacy?

Maintain a professional tone, but do not answer substantive questions without legal counsel present. Anything said during a DEA inspection or audit may be used in later administrative or criminal cases. Reach out to an experienced DEA investigation attorney as soon as possible before giving any interviews or explanations.

Can the DEA revoke my registration without a criminal conviction?

Yes. The DEA may suspend or revoke a registration if it determines that ongoing registration conflicts with the public interest. Administrative proceedings follow different standards than criminal cases and do not require proof beyond a reasonable doubt.

How did the Supreme Court's decision in Ruan v. United States affect DEA prosecutions?

The Supreme Court ruled that prosecutors need to demonstrate that a physician knowingly or intentionally prescribed controlled substances without authorization. However, a good-faith belief that the prescriptions were medically justified can act as a defense against criminal charges under the Controlled Substances Act.

Can Prescription Drug Monitoring Program (PDMP) data alone prove wrongdoing?

While PDMP data may reveal unusual prescribing patterns, being a statistical outlier doesn't necessarily indicate criminal intent. Providers frequently have valid reasons for their prescribing behavior, considering factors like specialty, patient demographics, location, or treatment approach. A solid defense can contest the government's interpretation of this prescribing data.

Defense Strategies That Matter

Building and Presenting the Good Faith Record

Good-faith belief in the legitimacy of prescribing or dispensing is now a valid defense, but it protects a registrant only if documented. Every red flag investigated and resolved needs to be documented at the time, with specifics.

This creates the evidence of good faith that Ruan now protects. The defense begins well before any indictment, in the prescription logs, patient charts, PDMP screenshots, and prescriber communications that exist at the time of the audit.

Challenging the Government's Statistical Methodology

PDMP outlier data does not prove criminal intent. A provider whose prescribing volume exceeds regional averages may be treating a specialized patient population, operating in an underserved area, or filling a legitimate gap in pain management care.

Statistical deviation alone is not evidence of a scheme. A defense team with access to biostatistics or pharmacy practice experts can challenge whether the government's data analysis accounts for the clinical context of the practice being investigated.

Controlling What is Said and Produced During the Audit

The single most consequential decision in a DEA audit is whether to answer questions without counsel present. Statements made to diversion investigators are not protected, and they cannot be taken back.

Retaining counsel before responding to any DEA request for records or an interview, including requests that appear informal, preserves options that, once forfeited, cannot be recovered.

Contesting Registration Revocation as a Separate Front

Challenging an immediate suspension order or an order to show cause before an administrative law judge is a separate proceeding that runs concurrently with any criminal matter. Both require active defense.

Audit Resolved Without Criminal Referral

A pain management physician in a rural county received notice of a DEA diversion investigation following PDMP analysis that flagged the practice as a statistical outlier for Schedule II opioid prescriptions.

The physician's patient volume in that specialty was legitimately higher than regional norms because the practice was the only dedicated pain management provider within a sixty-mile radius.

Defense counsel was retained before the physician responded to any DEA communications. Counsel commissioned an independent review of 200 randomly selected patient charts from the flagged period.

The review found thorough documentation of patient histories, physical examination findings, failed conservative treatments, PDMP checks, and individualized dosing rationale in each file.

Counsel presented the chart review, a demographic analysis of the patient population establishing the geographic access gap, and a comparison of the physician's prescribing patterns against specialty-specific rather than general-practice norms.

The DEA closed the investigation without referring the matter for criminal prosecution. The physician's registration remained intact.

The outcome turned on three factors: counsel retained before any statements were given, contemporaneous documentation supporting good faith, and expert analysis reframing the government's statistical narrative. Contact the attorneys at Eisner Gorin LLP today for a consultation.

Prescription Drug Monitoring